A collaboration between a UK research team and international medicine manufacturers may lead to a ‘milestone’ treatment for epilepsy. This treatment appears more bearable than current epilepsy medicines – and is based on cannabis.
A research team at the University of Reading performed the research, which was recently published in The British Journal of Pharmacology. Their research explored the use of cannibidivarin – a natural chemical called a ‘cannabinoid’ from the cannabis plant.
Cannibidivarin does not have psychoactive properties (anyone taking a drug based on this chemical will not feel ‘high’ as a result). It appears to reduce seizure frequency in laboratory animals with epilepsy and has fewer side-effects than traditional epilepsy medicines. The new drug can also be safely combined with regular medications.
Lead study author, Dr Ben Whalley, said: “This is an enormously exciting milestone in our investigations into non-psychoactive elements of cannabis as treatments for epilepsy. Our work has highlighted the potential for a solution based on cannabinoid science. It has shown that cannabidivarin is the most effective and best tolerated anticonvulsant plant cannabinoid investigated to date.””
“VCU study is first to test anticonvulsant potential of marijuana and brain recurrent seizures.
Ingredients in marijuana and the cannabinoid receptor protein produced naturally in the body to regulate the central nervous system and other bodily functions play a critical role in controlling spontaneous seizures in epilepsy, according to a new study by researchers at Virginia Commonwealth University.
The study, the first to look at marijuana and the brain’s cannabinoid system in live animals with spontaneous, recurrent seizures, suggests new avenues that researchers can explore in their search for more-effective drugs to treat epileptic patients who don’t respond to today’s anticonvulsant medications or surgery.
The results appear in the Oct. 1 issue of the Journal of Pharmacology and Experimental Therapeutics.
“Although marijuana is illegal in the United States, individuals both here and abroad report that marijuana has been therapeutic for them in the treatment of a variety of ailments, including epilepsy,” says Dr. Robert J. DeLorenzo, professor of neurology in the VCU School of Medicine.
“If we can understand how marijuana works to end seizures, we may be able to develop novel drugs that might do a better job of treating epileptic seizures.”
Epilepsy is one of the most common neurological conditions, characterized by spontaneously recurrent seizures. Approximately 1 percent of Americans have epilepsy, and 30 percent of those patients are resistant to conventional anticonvulsant drug treatments.
Cannabinoids have been used as a natural remedy for seizures for thousands of years, and studies since at least 1974 have found that the primary psychoactive compound in marijuana displays anticonvulsant properties.”
“A California father’s desperate quest to find a viable solution to his young son’s rare form of epilepsy has led him to incredible success in medicinal marijuana. The Los Angeles Times (LAT) reports that Jason David’s son Jayden now functions normally, eats solid food, and takes only four prescription medications for his condition rather than the 22 he had been takingprior to starting the cannabis protocol.Young Jayden suffers from an extremely rare, and potentially fatal, epileptic condition known as Dravet syndrome that is categorized as a “catastrophic form of intractable epilepsy.” For Jayden, symptoms of the condition have included things like intense “grand mal” seizure fits, continuous muscle twitching, inability to respond to or interact with others, difficulty chewing, and frequent screaming episodes.
According to Jayden’s father Jason, Jayden had spent most of his life either sleeping or seizing, which put incredible strain on the family as it unsuccessfully tried using prescription drug after prescription drug to at least ease Jayden’s symptoms. But Jayden’s condition only got progressively worse in response to pharmaceuticals, which led Jason to actually consider committing suicide as he says he simply could no longer bear watching his son suffer in this horrific way.
After praying intensely about the situation and meeting with their local religious congregation for guidance; however, the Davids stumbled upon medical marijuana, and particularly cannabidiol (CBD), one of the many cannabinoid compounds naturally found in certain varieties of marijuana. Following a period of heavy research into the history and effectiveness of CBD, Jason decided it was worth giving the treatment a try with his son — and upon doing so, the Davids observed an almost immediate improvement in Jayden’s condition.”
“Six-year-old Charlotte Figi, a picture of precious in her “Gatsby”-style bob and blue toenails, stands patiently as her mother reaches up her dress to change her out of her soiled Pull-Ups. – Charlotte never says a word. She hasn’t in the past hour, and won’t for at least another 30 minutes, when she finally whispers the name of a visitor who is about to leave.
In the Figi household, these are signs of progress: Charlotte saying something. Charlotte eating and drinking. Charlotte standing and walking.
Charlotte breathing.
About 18 months ago, in the winter of 2011, Paige and Matt Figi signed a “do not resuscitate” order telling medical personnel to forgo life-saving measures for their daughter and let fate take its course.
They’d done all they could to control the seemingly endless, violent seizures that hit Charlotte 20, 40, 60 times a day. They put her on an extreme diet. They tried at least a dozen medications, many with harmful side effects. Despite some promising starts, nothing worked. And the rescue medications they were giving her to stop the seizures in fact stopped her breathing. CPR brought her back to life more than once.
After years of watching a cruel, incurable genetic disorder called Dravet Syndome rob their daughter of her basic bodily functions and send her into convulsions that caused head injuries and broken teeth, they had reached the end.
“We really thought, this is a horrible existence; she’s not going to live much longer.” Paige says. “This is not a life for her. This is torture. She is suffering all day. I’m not OK with this. She wasn’t even human anymore. She’d lie in my arms drooling, seizing, screaming and crying.”
Then, in an act of desperation, or inspiration – or maybe both – Matt called Paige from overseas, where he was working, and suggested a radical approach to Charlotte’s treatment.
“We need to try cannabis for Charlotte,” he told Paige. “We live in a compassionate state.”
Fifteen months later, the little girl with the DNR order is standing in the kitchen of their Black Forest home with her mother getting her Pull-Ups changed, cuddling in the arms of a visitor, playing with toys and strategically pushing the buttons on her “talker,” an electronic device that communicates when Charlotte can’t.
Her seizures have dropped from 1,200 a month to three, and the ones she has are shorter in duration and less severe. She’s off all the other medications with their troubling side effects. And, as one of the youngest medical marijuana patients in Colorado, her dramatic turnaround is starting to draw national attention, with a CNN report on the horizon.”
“A new study published in the March issue of The American Journal of Pathology suggests that cortical type 2 cannabinoid (CB2) receptors might serve as potential therapeutic targets for cerebral ischemia.
Researchers found that the cannabinoid trans-caryophyllene (TC) protected brain cells from the effects of ischemia in both in vivo and in vitro animal models. In rats, post-ischemic treatment with TC decreased cerebral infarct size and edema. In cell cultures composed of rat cortical neurons and glia exposed to oxygen-glucose deprivation and reoxygenation (OGD/R), TC decreased neuronal injury and mitochondrial depolarization, specifically through type 2 cannabinoid receptor (CB2R) pathways.
“To our knowledge, novel data presented in this study provide evidence for the first time supporting a previously unappreciated role of cortical CB2R, especially neuronal CB2Rs, in ischemia,” says lead investigator Won-Ki Kim, PhD, of the Department of Neuroscience, College of Medicine, Korea University in Seoul. “This study suggests that further investigation is warranted to establish the clinical usefulness of TC as a preventative and therapeutic agent for treatment of stroke.””
“Cannabis is in the news again for its purported medicinal benefits, with researchers in Israel last week indicating it may help prevent trauma to the brain in certain circumstances and may also help with cardiac problems. A few months ago an English pharmaceutical company that manufactures cannabinoids announced it was developing a new treatment for epilepsy using them.”
“Prof. Yosef Sarne in the Adelson Center for the Biology of Addictive Diseases in the Department of Physiology and Pharmacology at Tel Aviv University says that cannabis has neuro-protective qualities. He has found that extremely low doses of tetrahydrocannabinol or THC- the psychoactive component of marijuana- can protect the brain from long-term cognitive damage in the wake of injury from hypoxia (lack of oxygen), seizures, or toxic drugs.”
“GW Pharmaceuticals (GWPH) is an UK-based biopharmaceutical company focused on the discovery and development of cannabinoid-based products for a wide range of indications. GW has established a technology platform based on genetically modified cannabis plants and has become a leader in plant-derived cannabinoid therapeutics.
GW’s lead program is Sativex, a cannabis extract based oromucosal spray whose main actives are the cannabinoids delta-9- tetrahydrocannabinol (THC), and cannabidiol (CBD). It is approved for the treatment of multiple sclerosis (MS) spasticity in 21 countries outside of the U.S and already marketed in seven countries (eight following Italian launch in Q213).
…While MS spasticity has provided proof-of-concept in the worldwide approvability of Sativex, a more meaningful commercial opportunity is in the treatment of opioid-refractory cancer pain. Sativex has been tested in two Phase II trials in cancer pain. The trials have demonstrated that Sativex is safe and effective when used in addition to opioids in patients whose cancer pain is not sufficiently managed by opioids alone. Based on these results, GW has initiated three Phase III trials. The first two are expected to complete during 2014 and support an FDA filing.”
“A mouth spray containing cannabinoids is effective in reducing pain in cancer patients who are still in pain despite using opioid medicines, according to a new study published in The Journal of Pain.”
“The oral mucosal spray known as nabixmols, which is marketed under the trade name Sativex, contains a formulation of cannabinoids, marijuana’s most active ingredients.”
“Neuropathic pain caused by chemotherapy limits dosing and duration of potentially life-saving anti-cancer treatment and impairs quality of life. Chemotherapeutic neuropathy responds poorly to conventional treatments, and there is an urgent medical need for new treatments. Recent preclinical studies demonstrate that cannabinoid agonists suppress established chemotherapy-evoked neuropathy.
This was a pilot trial to begin to investigate a currently available cannabinoid agent, nabiximols (oral mucosal spray containing cannabinoids), in the treatment of chemotherapy-induced neuropathic pain.
CONCLUSION:
Chemotherapy-induced neuropathic pain is particularly resistant to currently available treatments. This pilot trial found a number needed to treat of five and an average decrease of 2.6 on an 11-point NRS-PI in five “responders” (as compared with a decrease of 0.6 with placebo) and supports that it is worthwhile to study nabiximols in a full randomized, placebo-controlled trial of chemotherapy-induced neuropathic pain.”
“Future research targeting cannabinoids and their receptors may lead to evidence-based treatments for patients diagnosed with post-traumatic stress disorder (PTSD), according to clinical trial data published in May in the journal Molecular Psychiatry.
Investigators at the New York University School of Medicine reported that subjects diagnosed with PTSD typically possess elevated quantities of endogenous cannabinoid receptors in regions of the brain associated with fear and anxiety. Investigators also determined that many of these subjects experience a decrease in their natural production of anandamide, an endogenous cannabinoid neurotransmitter, resulting in an imbalanced endocannibinoid regulatory system.
Researchers speculated that an increase in the body’s production of cannabinoids would likely restore subjects’ natural brain chemistry and psychological balance. They affirmed, “[Our] findings substantiate, at least in part, emerging evidence that … plant-derived cannabinoids such as marijuana may possess some benefits in individuals with PTSD by helping relieve haunting nightmares and other symptoms of PTSD.”
Authors concluded: “The data reported herein are the first of which we are aware of to demonstrate the critical role of CB1 (cannabinoid) receptors and endocannabinoids in the etiology of PTSD in humans. As such, they provide a foundation upon which to develop and validate informative biomarkers of PTSD vulnerability, as well as to guide the rational development of the next generation of evidence-based treatments for PTSD.”
